Metabolic Research Compounds —
Where to Start & What to Compare
The fastest-moving category in research peptides. From FDA-approved GLP-1 agonists to frontier exercise mimetics — how the mechanisms differ, what the evidence actually shows, and how to pick the right starting point.
At a Glance
Metabolic research compounds are often lumped together under the GLP-1 umbrella, but the category is much broader. There are five genuinely distinct mechanisms at work — and choosing between them depends entirely on what metabolic question you're actually trying to answer.
Incretin Agonism
Semaglutide, tirzepatide, retatrutide, cagrilintide — receptor agonists targeting GLP-1, GIP, glucagon, and amylin pathways. The most clinically advanced group.
Lipolysis & Fat Metabolism
AOD-9604 — GH-derived lipolytic fragment. Fat oxidation without IGF-1 elevation or insulin effects. Phase 2 human data.
CNS Appetite Modulation
Tesofensine — triple monoamine reuptake inhibitor. Addresses the reward and motivation dimension of appetite centrally, not peripherally.
Mitochondrial / Exercise Mimetics
BAM15, SLU-PP-332, MOTS-c — uncoupling, ERRα activation, and AMPK signaling. Increase energy expenditure through different mitochondrial mechanisms.
Metabolic Epigenetics
5-Amino-1MQ — NNMT inhibition reprogramming adipocytes at the chromatin level. Fat reduction without appetite suppression.
Semaglutide, tirzepatide, retatrutide, and cagrilintide are often described as a progression — each generation adding receptor targets and improving outcomes. They're also suited to different research questions.
| Compound | Receptors | Max Weight Loss | Evidence Level | Best Research Use |
|---|---|---|---|---|
| Semaglutide | GLP-1 only | ~15–17% | FDA Approved | Reference compound — most clinical data, cardiovascular, renal, liver outcomes |
| Tirzepatide | GLP-1 + GIP | ~22.5% | FDA Approved | Dual agonism mechanism, GIP-specific effects, head-to-head vs semaglutide |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24.2% (Phase 2) | Phase 2 | Glucagon-driven thermogenesis, triple agonism frontier, highest weight loss data |
| Cagrilintide | Amylin (RAMP/CTR) | 22.7% (as CagriSema) | Phase 3 Active | Amylin-GLP-1 non-overlapping satiety pathways |
AOD-9604 — Isolated Lipolysis: When fat metabolism research needs to be separated from appetite suppression. Drives lipolysis via beta-3 adrenergic stimulation without touching IGF-1 or insulin sensitivity. Phase 2 human fat loss data confirmed.
Tesofensine — The CNS Angle: When the research focus is the central reward and motivation dimension of eating behavior. Triple monoamine mechanism produced 10–13% weight loss in Phase 2b from a purely CNS mechanism.
BAM15 — Mitochondrial Uncoupling: When the research objective is increasing metabolic rate through a thermogenic, non-appetite mechanism. Forces cells to burn more fuel by uncoupling the mitochondrial proton gradient. Insulin sensitivity improvement is a secondary finding.
SLU-PP-332 — Exercise Transcription: When the research question is the molecular basis of exercise adaptation. Activates ERRα — the transcription factor governing the entire oxidative metabolism gene network that aerobic exercise activates.
5-Amino-1MQ — Adipocyte Reprogramming: When the research angle is the epigenetic basis of adiposity. NNMT inhibition reverses chromatin-level changes that lock obese fat cells in energy-storing mode — fat reduction without appetite suppression.
| Research Objective | Starting Compound |
|---|---|
| Benchmark GLP-1 | Semaglutide — most data, broadest indication coverage, best comparator |
| Dual incretin mechanism | Tirzepatide — GIP + GLP-1 effects, head-to-head vs semaglutide established |
| Thermogenesis + appetite | Retatrutide — glucagon component adds energy expenditure; highest weight loss data |
| Non-overlapping satiety | Cagrilintide (with semaglutide) — amylin vs GLP-1 hypothalamic satiety |
| Isolated fat metabolism | AOD-9604 — lipolysis without IGF-1 or insulin confounds |
| CNS / reward / appetite | Tesofensine — central monoamine mechanism, dopamine reward pathway |
| Thermogenesis only | BAM15 — direct mitochondrial uncoupling, no appetite or hormone effects |
| Exercise adaptation | SLU-PP-332 or MOTS-c — ERRα transcription vs AMPK kinase activation |
| Adipocyte biology / epigenetics | 5-Amino-1MQ — NNMT inhibition, chromatin-level fat cell reprogramming |
All compounds listed are for laboratory research use only. Not for human or veterinary use. Information based on publicly available scientific literature as of 2026. · Helixera Labs LLC © 2026